Valuation: Pluristem Therapeutics

Market Cap 2.26Cr 1.95Cr 1.82Cr 1.67Cr 3.14Cr 214.61Cr 3.19Cr 21Cr 8.39Cr 107.57Cr 8.47Cr 8.28Cr 355.62Cr P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 3.6Cr 3.11Cr 2.91Cr 2.67Cr 5.02Cr 342.5Cr 5.1Cr 34Cr 13Cr 171.67Cr 14Cr 13Cr 567.52Cr EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.43%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 54 01/02/2015
Director/Board Member 56 06/01/2021
Director/Board Member 64 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 1.95Cr
+0.99%+1.78%+4.07%+16.73% 4.87TCr
+0.19%+5.58%+466.51%+568.00% 4.21TCr
+1.45%+0.34%+31.79%+7.54% 3.83TCr
+4.81%+9.51%+16.01%+84.54% 3.75TCr
+2.21%+4.89%+17.24%+51.64% 3.14TCr
+1.81%+4.05% - - 1.65TCr
-0.17%+1.46%+36.55%+124.86% 1.63TCr
-0.11%+2.41%+6.24%+18.87% 1.4TCr
-1.31%+13.07%+75.53%+28.07% 1.27TCr
Average +1.37%+3.06%+81.74%+112.53% 2.86TCr
Weighted average by Cap. +1.51%+2.31%+98.85%+134.65%

Financials

2024 2025
Net sales 3L 3L 3L 2L 5L 3.1Cr 5L 30.9L 12.13L 1.56Cr 12.24L 11.97L 5.14Cr 13.36L 11.56L 10.79L 10L 18.62L 13Cr 18.92L 1.27Cr 49.7L 6.37Cr 50.17L 49.07L 21Cr
Net income -2.09Cr -1.81Cr -1.69Cr -1.55Cr -2.91Cr -198.79Cr -2.96Cr -20Cr -7.77Cr -100Cr -7.84Cr -7.67Cr -329.41Cr -2.26Cr -1.95Cr -1.82Cr -1.67Cr -3.15Cr -214.93Cr -3.2Cr -21Cr -8.4Cr -107.73Cr -8.48Cr -8.29Cr -356.14Cr
Net Debt -4L -3L -3L -3L -5L -3.55Cr -5L -35.35L -13.87L -1.78Cr -14.01L -13.7L -5.88Cr 1.34Cr 1.16Cr 1.09Cr 99.57L 1.87Cr 127.88Cr 1.9Cr 13Cr 5Cr 64Cr 5.05Cr 4.94Cr 211.9Cr
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-